Abeona Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat Abeona Therapeutics de winst en omzet met respectievelijk 53.4% en 62.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 56.3% per jaar.
Belangrijke informatie
53.4%
Groei van de winst
56.3%
Groei van de winst per aandeel
Biotechs winstgroei | 27.3% |
Inkomstengroei | 62.7% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | 31 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?
Sep 23We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
May 01We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
Jan 04Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation
Aug 16Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?
Mar 31Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value
Oct 19Abeona Therapeutics stock continues recent strong run, shares rise ~10%
Oct 04Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M
Aug 11Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement
Jul 20Abeona crashes 21% as reverse stock split takes effect
Jul 05Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely
Mar 02Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Aug 17Abeona Therapeutics shares rise after letter to stockholders
May 26Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt
Apr 28Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)
Feb 21How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 19What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?
Dec 15Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 71 | -40 | -31 | -59 | 6 |
12/31/2025 | 14 | -71 | -52 | -66 | 6 |
12/31/2024 | 0 | -62 | -60 | -64 | 6 |
6/30/2024 | N/A | -53 | -44 | -42 | N/A |
3/31/2024 | 4 | -77 | -41 | -40 | N/A |
12/31/2023 | 4 | -54 | -37 | -37 | N/A |
9/30/2023 | 4 | -45 | -42 | -42 | N/A |
6/30/2023 | 4 | -39 | -43 | -43 | N/A |
3/31/2023 | 1 | -31 | -42 | -42 | N/A |
12/31/2022 | 1 | -43 | -44 | -43 | N/A |
9/30/2022 | 4 | -83 | -63 | -60 | N/A |
6/30/2022 | 4 | -84 | -67 | -63 | N/A |
3/31/2022 | 3 | -91 | -70 | -66 | N/A |
12/31/2021 | 3 | -85 | -70 | -66 | N/A |
9/30/2021 | 3 | -54 | -38 | -37 | N/A |
6/30/2021 | 10 | -54 | -38 | -37 | N/A |
3/31/2021 | 10 | -52 | -37 | -35 | N/A |
12/31/2020 | 10 | -84 | -36 | -35 | N/A |
9/30/2020 | 7 | -85 | -49 | -48 | N/A |
6/30/2020 | N/A | -95 | -57 | -55 | N/A |
3/31/2020 | N/A | -106 | -67 | -61 | N/A |
12/31/2019 | N/A | -76 | -69 | -63 | N/A |
9/30/2019 | 0 | -77 | -83 | -66 | N/A |
6/30/2019 | 2 | -76 | -74 | -56 | N/A |
3/31/2019 | 2 | -65 | -67 | -50 | N/A |
12/31/2018 | 3 | -57 | -59 | -39 | N/A |
9/30/2018 | 3 | -48 | -36 | -27 | N/A |
6/30/2018 | 1 | -37 | -33 | -25 | N/A |
3/31/2018 | 1 | -33 | N/A | -21 | N/A |
12/31/2017 | 1 | -27 | N/A | -23 | N/A |
9/30/2017 | 1 | -26 | N/A | -21 | N/A |
6/30/2017 | 1 | -23 | N/A | -18 | N/A |
3/31/2017 | 1 | -22 | N/A | -16 | N/A |
12/31/2016 | 1 | -22 | N/A | -13 | N/A |
9/30/2016 | 1 | -17 | N/A | -12 | N/A |
6/30/2016 | 1 | -21 | N/A | -11 | N/A |
3/31/2016 | 1 | -18 | N/A | -10 | N/A |
12/31/2015 | 1 | -15 | N/A | -10 | N/A |
9/30/2015 | 1 | -25 | N/A | -9 | N/A |
6/30/2015 | 1 | -21 | N/A | -6 | N/A |
3/31/2015 | 1 | -30 | N/A | -5 | N/A |
12/31/2014 | 1 | -30 | N/A | -2 | N/A |
9/30/2014 | 1 | -19 | N/A | -1 | N/A |
6/30/2014 | 1 | -17 | N/A | -2 | N/A |
3/31/2014 | 1 | -3 | N/A | 0 | N/A |
12/31/2013 | 2 | 2 | N/A | 0 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ABEO de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ABEO ( 62.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van ABEO ( 62.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ABEO naar verwachting over 3 jaar hoog zal zijn